Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Innovotech Inc V.IOT

Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.


TSXV:IOT - Post by User

Bullboard Posts
Post by DerekForealon Mar 13, 2015 3:34pm
156 Views
Post# 23519233

Interesting Company

Interesting Company Set aside the evident cash on hand problem, this company is more than viable for a less than 500k market cap stock. Low number of s/o and growth potential.  Last update they said that the signed contracts from new clients increased and the company forecasts increased revenues for next three quarters. “Contract research revenue for the second half of 2014 will be strong" 

By looking at their 3 last quarters, it is evident that they feel the cash flow pressure and are controlling costs. We will see if they are able to pull it off in Q4 (coming out soon). 

Ultra speculative stock with growth potential on their contract research segment and we might have a surprise on the licensed product/technology side. The company burned a lot of cash on patents... hopefully it will pay off. 

GLTA
Bullboard Posts